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Abstract 
BACKGROUND: The fungal disease caused by invasive fungus Saprochaete capitata is becoming an 
increasingly popular infection. Fungal pathogens mainly occur in patients with immunocompromised disorders 
such as hematologic malignancies, acute myeloid leukemia, transplant patients.  
CASE REPORT: In this study, we presented a COPD patient infected with S. capitata. At the first check, the 
patient showed cough, dyspnea, chest pain on both sides. The clinical laboratory test result was characterized 
with high White blood cell (12.8 G/L), HIV negative. The X ray showed bronchitis and emphysema. Bronchoscopy 
illustrated bronchial mucositis. CT scanner demonstrated pneumonia with fuzzy nodular lesions and thick 
interstitial organization in both lungs. The patient was treated with ciprofloxacin 800 mg/day; cefuroxime 2250 
mmg/day. However, the fever appeared 2 weeks thereafter. The S. capitata was discovered in the bronchial fluid. 
The patient was then treated with fluconazole 400 mg/day for 14 days. At the end of treatment, all signs and 
symptoms of S. capitata infection disappeared and the patient recovered.  
CONCLUSION: This case study showed that S. capitata infection can occur in the COPD patients and 
fluconazole is a pertinent drug for treatment of the infection. 
 
 
 
Introduction 
 
Candida and Aspergillus spp. are mainly the 
causes of invasive fungal infections in hospitals. 
However, infection with rare fungal pathogens has 
become more popular in recent years. Infections 
caused by Saprochaete capitata are one of the 
emerging diseases. S. capitata, previously known as 
Geotrichum capitatum, Trichosporon capitatum, 
Blastoschizomyces capitatus, Dipodascus capitatus, 
is a non-fermentative, urease-negative ascomycetous 
yeast classified in Saccharomycetaceae family [1], [2], 
[3], [4], [5], [6], [7]. S. capitata fungus grows well in the 
Saboraud agar, their colonies are similar to yeast, but 
their morphology characterizes with long and short 
segments with different sizes. This fungus is mainly 
found in natural environments such as soil, sand and 
wood pulp [8]. In addition, it has also been found in 
poultry feces, gastrointestinal tract, respiratory tract, 
and is a part of the normal microflora of human skin 
[9]. They are known as the fungi that live in the 
respiratory tract and digestive tracts of humans, they 
are invasive pathogens like other yeast species [10]. 
S. capitata infection is mainly seen in patients 
with neutrophil leukemia (87%), more rarely in 
patients with other non-hematological diseases such 
as diabetes, neuralgia, organ transplantation and 
inflammations [11] (Table 1). In this report, we 
described a case of fungal infection caused by S. 
capitata in COPD patients. 
Table 1: Some report cases cause by Saprochaete capitata 
No. Case Age Symptoms/ problems Treatment References 
1 
Acute myeloid 
leukemia 
41 Erythema, high fever 
caspofungin and 
liposomal amphotericin 
B 
[12] 
2 
Kidney 
transplant 
82 
hypertensive 
nephrosclerosis 
liposomal amphotericin 
B 
[13] 
3 
Burkitt 
lymphoma 
74 
fever and central nervous 
system 
fluconazole and 
caspofungin 
[12] 
4 
Acute myeloid 
leukemia 
57 
Fever, diarrhoea and skin 
rash 
levofloxacin 
fluconazole 
[14] 
5 
Pneumonia, 
asthama 
86 
shortness of breath, 
productive cough and 
fatigue 
itraconazole [15] 
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Clinical Case 
 
An 80-year-old man was diagnosed with 
COPD and Gout 10 years ago. The patient came to 
the hospital with productive cough, dyspnea, chest 
pain on both sides a week before. Examination 
revealed symptoms including vesicular breathing, 
coarse crackle and wheeze in both lungs, no 
hypertension, non-diabetic, no fever. The laboratory 
blood test results were: Red blood cell 4.36 T/L, 
hematocrit 138 g/l, White blood cell 12.8 G/L 
(Lymphocyte 17.4% and Granulocyte 74.1%), HIV 
negative, Genxpert DPG (-), AFB (-). The X-ray 
showed bronchitis and emphysema. Bronchoscopy 
illustrated bronchial mucositis (Figure 1).  
 
Figure 1: X – ray of patient before treatment 
 
CT scanner demonstrated the pneumonia 
with fuzzy nodular lesions and thick interstitial 
organization in both lungs (Figure 2). The patient was 
treated with ciprofloxacin 800mmg/day; cefuroxime 
2250 mmg/day; ventolin 40mg/ day; pulmicort 500mg; 
salbutamol 16mg/ day. 
 
Figure 2: CT scan of the patient before treatment 
After 2 weeks, cough and shortness of breath 
decreased, fever, however, developed. The patient 
was then treated with methylprednisolon 40 mg per 
day for 7 days. After the cease of drug, fever again 
developed. Therefore, the patient was treated with 
raxadin 2000 mmg + moxifloxacin 400 mmg + 
doxycyclin 1000 mmg per day for another 7 days. The 
patient was still feverish, tired, screeching and snoring 
was in both sides of the lung. The phlegm of patient 
was sampled and cultured to find fungi. S. capitate 
was detected by semi-automatic Vitek system (Figure 
3 and 4), the blood cultured showed negative.  
 
Figure 3: Saprochaete capitata on SAB media at 72 hour at 37°C 
 
After 14 days of treatment with fluconazol 400 
mg per day, the patient recovered and all the 
symptoms disappeared. The phlegm cultured showed 
negative. 
 
Figure 4: Saprochaete capitata staining with lactophenol cotton blue 
under microscope (X 400) 
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Discussion 
 
Saprochaete capitata has determined 
considerable taxonomic evaluation [16]. Evaluation of 
this fungus under microscopy showed the septal 
pores and cell wall structurewith lots of arthroconidia 
and few blastoconidia [1]. In our case, S. capitata 
grow well on the Saboraud agar at 37°C, the colonies 
are similar to those of yeast. However, it is, with 
different dimensions of segments under microscope 
(Figure 4), similar to the filamentous fungi. 
Conventionally, detection of these fungi in the culture 
medium basing on their morphology is an important 
diagnosis. Using automatic or semi-automatic system 
may be a great choice. The Vitek 2 system version 
07.01 was used to confirm S. capitata. This system 
has been shown to possess an accuracy rate of 98%. 
Besides, D 32C (bioMérieux), and RapID Yeast Plus 
(Innovative Diagnostic Systems) systems also were 
applied to diagnosis of this fungus [17], [18]. 
Unfortunately, their mophology is very similar to that 
of S. clavata [17]. 
S. capitata infection is becoming an emerging 
disease, particularly in immunocompromised such as 
haematological malignancies, asscociated cancer and 
onychomycosis [19]. Factors such as extended 
neutropenia, active chemotherapy, broad-spectrum 
antibiotics use and reduced local defense system by 
breaking down the skin and mucosa were mainly 
beneficial factors for this infection [20]. The 
haematological malignancy including acute leukemia 
is the disease in the most popular patients and 
estimated incidence is around 0.5% [1], [21]. 
Extremely, all of breaking through infections with 
acute leukemia developed in patients who were in 
intentive chemotherapy [1]. Moreover, broad spectrum 
antibiotic was used for treatment of all patients who 
developed neutropenic fever. The 30-day mortality is 
30 days it related with invasive disease ranges from 
60 – 80% [1]. In this case, the patient was treated with 
two antibioticsfor 14 days. The symptoms decrease at 
the end of antibiotic treatment. However, the patient 
appeared fever in the afternoon. This case indicates 
the antibiotics ciprofloxacin and cefuroxime are not 
really effective with S. capitata. Positive blood culture 
was found in almost of case infection with 77.3%. 
While our case showed negative in blood culture. The 
pneumonia in S. capitata usually associated in 
haematological malignancies or multiple diseases. It 
could make the infection becomes more severse [15].  
The in vitro study of susceptibility S. capitata 
is quite weak. Published literature showed that S. 
capitata is susceptible to flucytosine (MIC values 0.25-
0.5 mg/mL), itraconazole (MIC values 0.12-0.50 
mg/mL), voriconazole (MIC values 0.25-0.5 mg/mL) 
and posaconazole (MIC values 0.03-0.25 mg/mL). 
However, these organisms are less susceptible to 
fluconazole with a MIC between 16 and 32 mg/mL in 
most studies [3], [22], [23]. Amphotericin B was 
effective in inhibition of these fungus only with high 
concentration (MIC values 0.5-2.0 mg/mL) [24]. S. 
capitata was demonstrated to intrinsically resist to 
echinocandins [25]. Girmenia et al. reported that 
amphotericin B, flucytosine, fluconazole, itraconazole, 
and voriconazole hadhigh efficacy against S. capitata 
isolates. Other authors indicated that amphotericin B 
and voriconazole were more potent than other drugs 
in inhibition of S. capitata [23]. In these cases, 
demonstrated S. capitata reduce susceptive to 
anidulafungin at 8 mg/mL MIC value as expected. 
Fluconazole is less effective than itraconazole, 
voriconazole and azoles against S. capitata. The data 
of optimal treatment to S. capitata infection is not 
enough. In this infection indicated use of amphotericin 
B alone or in combination with flucytosine is a quality 
treatment. S. capitata infection treat with fluconazole 
and echinocandins were also quite good choice. 
Breakthrough infections of S. capitata reported in 
neutropenic patients collected echinocandins [7], [26], 
[27]. In our case, S. capitata was effectively treated 
with fluconazole 400 mg/day per 14 days, but it is 
need more evidence of MIC value. This case also 
demonstrates that antibiotic treatment of this infection 
only reduces some symptoms, but it is unable to 
thoroughly treat the infection. Identification of fungi is 
the most important for diagnosis and treatment. 
In conclusion, S. capitata infected mostly to 
haematological malignancies patients, also with 
immunosuppressive and immunocompetent patients. 
In this case, the COPD patient was infected with S. 
capitata, treated with fluconazole 400 mg/day. The 
signs and symptoms disappeared after 2 weeks. The 
MIC of S. capitata should be do in the further study. 
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